Prestige Biologics (334970) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, Prestige Biologics (334970) reported revenue of 12.5 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202512.5 billion KRW-33.7 billion KRW-27.5 billion KRW[source]
20242.2 billion KRW-33.4 billion KRW-29.4 billion KRW[source]
20231.7 billion KRW-22.1 billion KRW-18.0 billion KRW[source]
202216 million KRW-36.6 billion KRW-49.7 billion KRW[source]
20213.2 billion KRW-26.8 billion KRW-39.4 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025270.3 billion KRW135.1 billion KRW135.2 billion KRW[source]
2024289.4 billion KRW217.7 billion KRW71.7 billion KRW[source]
2023305.8 billion KRW206.0 billion KRW99.8 billion KRW[source]
2022258.1 billion KRW140.5 billion KRW117.6 billion KRW[source]
2021206.8 billion KRW99.9 billion KRW106.8 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice